epilepsy
Atalanta Therapeutics Moving KCNT1-Related Epilepsy RNAi Drug Toward IND Submission
In a mouse model, a single dose of ATL-201 durably suppressed seizures and improved behavior through six months, according to the firm.
Biogen Inks Deal to Commercialize Stoke Therapeutics' Dravet Syndrome ASO; Stoke Retains US Rights
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Atalanta Therapeutics Raises $97M in Series B Financing to Advance RNAi Therapies for CNS Diseases
Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.
GeneDx Launches Program to Boost Access to Exome Testing for Pediatric Epilepsy Patients
In partnership with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, the program will also contribute to GeneDx's rare disease database.
UniQure to Start Clinical Trial for Epilepsy Gene Therapy This Year
The FDA cleared the company's IND for AMT-260, a gene therapy designed to treat refractory mesial temporal lobe epilepsy by suppressing GLUK2 expression.